Regulatory GSK eyes October FDA verdict on chronic hep B drug PharmaphorumGSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.Infectious DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October. Infectious Disease Read full story Post navigation Previous: Merck KGaA and Remepy join forces to develop combo drug-digital therapiesNext: Coultreon banks $125M to support testing of former Galapagos immune drug Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026